Hi,
I'm not a financial analyst or advisor *please do your own research*
I've been a shareholder since July, in and out, so I might be biased but I think a lot of people are sleeping on this. I kind of don't wanna write this post because I wanna buy more shares before this explodes, but if I don't do it now I probably won't ever.
Genetic Technologies Limited is an Australian molecular diagnostics company, currently with a personalized breast cancer, and colorectal cancer genetic risk assessment that people can buy online = don't need a doctor's appointment. They have 8 new products coming soon.
The price is currently $5.04 and it officially started trending upwards again on no news, up 12% today. Friday it was at $4.50. They recently had an offering at $5.25 a share, so it's currently below the offering.
It ran 300% in July on news of a COVID-19 Polygenic Risk Score Test , but imo this is probably it's worst product on the pipeline. A press release update in January also made it run from $4.50 to $9.20. Their product release got pushed a few months so speculation dropped the price. As scientists, their marketing has not been the best. But, on February 1st they got a new CEO specialized in commercializing products with incentives if the share price is doubled and held there for at least 15 trading days.
They have done offerings that gives them cash for several years.
In december, the company entered a 3 year partnership agreement with Taliaz to distribute their core product PREDICTIX which uses pharmacogenomics, a combination of genetic, metabolic, clinical and demographic background data in conjunction with AI to enable more accurate prescriptions of anti-depressants. This product will be available the second half of 2021.
They will also be releasing their COVID-19 SDR Test, and new Germline Testing products for BRCA and Lynch Syndrome in parallel. All at the same time.
They are also currently developing a High Density/Multitest that includes: breast cancer, colorectal cancer, cardiovascular disease, type 2 diabetes, melanoma, prostate cancer, and COVID-19. This will be released at the end of the year/ early next year. This test will be the same price as the others.
As of December 31st, they have $16.4 million in cash to expand their products, and expansion of their products only increases their current cost of production by 10%.
investor presentation: https://e13609b8-ed51-46c1-8570-6819a0110aba.filesusr.com/ugd/e99219_0b5df5fa114a4975845ba39b313c09a9.pdf
The Bank of New York Mellon Corporation (BNYMC) have been increasing their shares all year and on January 25th 2021 they recently increased their shares to a voting power of 74.52%.https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02333617-3A559959?access_token=83ff96335c2d45a094df02a206a39ff4
This will run over 100% on any new PR.
The average Analyst Price Target is $25.65. This company is extremely undervalued and has a short volume ratio of 31%.
It ran over 100% twice since July and it's been fun.
*this is my first DD, I hope I did it right*
edit: websites:
they are also listed under ASX as GTG
https://www2.asx.com.au/markets/company/GTG
edit:
I'm not a financial advisor but I am a scientist!! I think this stock is very undervalued
Submitted February 08, 2021 at 07:52PM by lucyinthesky237 https://ift.tt/3p4AHfL
